Special Issue

The Role of Cost-Effectiveness Analysis for Patient-Centered Cancer Care in the Era of Precision Medicine

Message from the Guest Editors

Over the last few decades, the cost of cancer care has been constantly increasing. While changes in diagnostic and treatment paradigms have advanced cancer care and improved outcomes through precision medicine, appropriate resource allocation and determining the effectiveness of cancer care are priorities for ensuring sustainable healthcare systems. Additionally, costeffectiveness metrics can be used as tools to allow for patient-centered care by providing patients objective metrics for each treatment strategy so that they can have an active role in the decision process. Hence, there is a critical need to implement cost-effectiveness analyses to inform healthcare decisions in clinical practice. In this Special Issue, we seek innovative comparative and cost-effectiveness analysis studies to guide cancer management decisions and health policy. Therefore, this topic aims to share new frameworks and concepts to determine the most cost-effective diagnostic and treatment strategies to maximize the care of cancer patients and resource utilization.

Guest Editors

Dr. Laurent Dercle

Department of Radiology, New York-Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA

Dr. Randy Yeh

Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Dr. Fabrizio Toscano

Montefiore Medical Center, New York, NY, USA

Deadline for manuscript submissions

closed (20 May 2022)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/66824

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

